Vaxcyte (1PCVX) Stock Overview
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
1PCVX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeVaxcyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.00 |
| 52 Week High | US$55.50 |
| 52 Week Low | US$26.20 |
| Beta | 1.3 |
| 1 Month Change | -11.54% |
| 3 Month Change | 0.88% |
| 1 Year Change | 60.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 57.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1PCVX | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -8.9% | 0.7% | 1.6% |
| 1Y | 60.8% | 32.3% | 20.1% |
Return vs Industry: 1PCVX exceeded the Italian Biotechs industry which returned 32.3% over the past year.
Return vs Market: 1PCVX exceeded the Italian Market which returned 20.1% over the past year.
Price Volatility
| 1PCVX volatility | |
|---|---|
| 1PCVX Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IT Market | 8.2% |
| 10% least volatile stocks in IT Market | 3.1% |
Stable Share Price: 1PCVX has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1PCVX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 507 | Grant Pickering | vaxcyte.com |
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine.
Vaxcyte, Inc. Fundamentals Summary
| 1PCVX fundamental statistics | |
|---|---|
| Market cap | €6.50b |
| Earnings (TTM) | -€804.08m |
| Revenue (TTM) | n/a |
Is 1PCVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1PCVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$946.53m |
| Earnings | -US$946.53m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1PCVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 21:20 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxcyte, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Thomas Shrader | BTIG |
| Carter Gould | Cantor Fitzgerald & Co. |